{"nctId":"NCT02073682","briefTitle":"Cancer Venous Thromboembolism (VTE)","startDateStruct":{"date":"2015-07-16","type":"ACTUAL"},"conditions":["Venous Thromboembolism (VTE)","Deep Vein Thrombosis (DVT)","Pulmonary Embolism (PE)","Cancer"],"count":1046,"armGroups":[{"label":"Edoxaban group","type":"EXPERIMENTAL","interventionNames":["Drug: Edoxaban","Drug: Low molecular weight heparin"]},{"label":"Dalteparin group","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Dalteparin"]}],"interventions":[{"name":"Edoxaban","otherNames":["DU-176b"]},{"name":"Dalteparin","otherNames":["Active comparator"]},{"name":"Low molecular weight heparin","otherNames":["LMWH"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female subjects with age â‰¥ 18 years or the otherwise legal lower age according to the country of residence;\n* Confirmed acute lower extremity proximal DVT or PE for which long term treatment with low molecular weight heparin (LMWH) is indicated;\n* Cancer, other than basal-cell or squamous-cell carcinoma of the skin;\n* Able to provide written informed consent.\n\nExclusion Criteria:\n\n* Thrombectomy, insertion of a caval filter, or use of a fibrinolytic agent to treat the current (index) episode of DVT and/or PE;\n* Treatment with therapeutic doses of an anticoagulant other than that used for pretreatment of the current (index) VTE episode prior to randomization;\n* Active bleeding or high risk for bleeding contraindicating treatment with LMWH or edoxaban;\n* Any other contraindication listed in the local labeling of dalteparin, enoxaparin, or edoxaban;","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Adjudicated Recurrent Venous Thromboembolism (VTE) or Major Bleeding Event","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"67","spread":null},{"groupId":"OG001","value":"71","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Adjudicated Major Bleeding Events While on Treatment","description":"The primary safety endpoint was major bleeding events during the On-Treatment Study Period (defined as on-study drug or up to 3 days after the last dose of study drug).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32","spread":null},{"groupId":"OG001","value":"16","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Recurrent Venous Thromboembolism (VTE) During the Overall Study Period","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41","spread":null},{"groupId":"OG001","value":"59","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Recurrent Deep Vein Thrombosis (DVT) During the Overall Study Period","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"35","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Recurrent Non-Fatal Pulmonary Embolism (PE) During the Overall Study Period","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"24","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With VTE-Related Death","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Recurrent VTE, Major Bleed or All-Cause Death","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"235","spread":null},{"groupId":"OG001","value":"228","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":276,"n":522},"commonTop":["Deep vein thrombosis","Epistaxis"]}}}